Role of 11β-hydroxysteroid dehydrogenase in nongenomic aldosterone effects in human arteries

Hypertension

Volumn 35, Issue 5, 2000, Pages 1099-1104

  Alzamora, Rodrigo ^a   Michea, Luis ^a   Marusic, Elisa T ^a  

^a UNIVERSIDAD DE LOS ANDES   (Chile)

Author keywords

11 hydroxysteroid dehydrogenase; Aldosterone; Cortisol; Human; Muscle, smooth, vascular; Nongenomic; Sodium hydrogen antiporter

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 5 (N ETHYL N ISOPROPYL)AMILORIDE; ALDOSTERONE; ALDOSTERONE ANTAGONIST; CARBENOXOLONE; HYDROCORTISONE; MINERALOCORTICOID RECEPTOR; OXPRENOATE POTASSIUM; SPIRONOLACTONE; HSD11B1 PROTEIN, HUMAN; HYDROXYSTEROID DEHYDROGENASE; ISOENZYME; SODIUM PROTON EXCHANGE PROTEIN;

ADULT; ARTERY; ARTICLE; CELL PH; ENZYME ACTIVITY; FEMALE; FETUS; FLUOROMETRY; HORMONE ACTION; HUMAN; HUMAN TISSUE; NORMAL HUMAN; PRIORITY JOURNAL; PROTON SODIUM EXCHANGE; DRUG EFFECT; ION TRANSPORT; METABOLISM;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ALDOSTERONE; ARTERIES; HUMANS; HYDROXYSTEROID DEHYDROGENASES; ION TRANSPORT; ISOENZYMES; SODIUM-HYDROGEN ANTIPORTER;

EID: 0033625558     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.35.5.1099     Document Type: Article

References (39)

1. Grunfeld JP, Eloy L. Glucocorticoids modulate vascular reactivity in the rat. Hypertension. 1987;10:608-618.
2. Yagil Y, Krakoff LR. The differential effect of aldosterone and dexamethasone on pressor responses in adrenalectomized rats. Hypertension. 1988;11:174-178.
3. Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science. 1988; 242:583-585.
4. Edwards CR, Benediktsson R, Lindsay RS, Seckl JR. 11β-Hydroxysteroid dehydrogenases: key enzymes in determining tissue-specific glucocorticoid effects. Steroids. 1996;61:263-269.
5. Rupprecht R, Reul JM, van Steensel B, Sgengler D, Soder M, Berning B, Holsboer F, Damm K. Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. Eur J Pharmacol. 1993;247:145-154.
6. Takeda Y, Inaba S, Furukawa K, Miyamori I. Renal 11β-hydroxysteroid dehydrogenase in genetically salt-sensitive hypertensive rats. Hypertension. 1998;32:1077-1082.
7. Gómez-Sánchez EP, Gómez-Sánchez CE. Maternal hypertension and progeny blood pressure: role of aldosterone and 11β-HSD. Hypertension. 1999;33:1369-1373.
8. Walker BR. Defective enzyme-mediated receptor protection: novel mechanisms in the pathophysiology of hypertension. Clin Sci (Colch). 1993; 85:257-263.
9. White PC, Mune T, Agarwal AK. 11β-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev 1997;18:135-156.
10. Brem AS, Bina RB, Hill N, Alia C, Morris DJ. Effects of licorice derivatives on vascular smooth muscle function. Life Sci. 1997;60: 207-214.
11. Gómez-Sánchez EP, Gómez-Sánchez CE. Central hypertensinogenic effects of glycyrrhizic acid and carbenoxolone. Am J Physiol. 1992;263: E1125-E1130.
12. Wehling M. Specific, nongenomic actions of steroid hormones. Annu Rev Physiol. 1997;59:365-393.
13. Doolan CM, Harvey BJ. Modulation of cytosolic protein kinase C and calcium ion activity by steroid hormones in rat distal colon. J Biol Chem. 1996;271:8763-8767.
14. ATP channels by aldosterone in principal cells of frog skin. J Physiol (Lond). 1996;491:111-120.
15. Christ M, Douwes K, Eisen C, Bechtner G, Theisen K, Wehling M. Rapid effects of aldosterone on sodium transport in vascular smooth muscle cells. Hypertension. 1995;25:117-123.
16. Wehling M, Bauer MM, Ulsenheimer A, Schneider M, Neylon CB, Christ M. Nongenomic effects of aldosterone on intracellular pH in vascular smooth muscle cells. Biochem Biophys Res Commun. 1996;223:181-186.
17. 2+ in vascular smooth muscle cells. Circ Res. 1995;76:973-979.
18. Christ M, Eisen C, Aktas J, Theisen K, Wehling M. The inositol-1,4,5-trisphosphate system is involved in rapid effects of aldosterone in human mononuclear leukocytes. J Clin Endocrinol Metab. 1993;77: 1452-1457.
19. Christ M, Wehling M. Rapid actions of aldosterone: lymphocytes, vascular smooth muscle and endothelial cells. Steroids. 1999;64:35-41.
20. Maguire D, MacNamara B, Cuffe JE, Winter D, Doolan CM, Urbach V, O'Sullivan GC, Harvey BJ. Rapid responses to aldosterone in human distal colon. Steroids. 1999;64:51-63.
21. Gekle M, Silbernagl S, Wunsch S. Non-genomic action of the mineralocorticoid aldosterone on cytosolic sodium in cultured kidney cells. J Physiol (Lond). 1998;511:255-263.
22. Stewart PM, Rogerson FM, Mason JI. Type 2 11β-hydroxysteroid dehydrogenase messenger ribonucleic acid and activity in human placenta and fetal membranes: its relationship to birth weight and putative role in fetal adrenal steroidogenesis. J Clin Endocrinol Metab. 1995;80:885-890.
23. + exchange in segments of rat mesenteric artery. Am J Physiol. 1992;262:H1651-H1656.
24. Thomas JA, Buchsbaum RN, Zimniak A, Racker E. Intracellular pH measurements in Ehrlich ascites tumor cells utilizing spectroscopic probes generated in situ. Biochemistry. 1979;18:2210-2218.
25. Coirini H, Magarinos AM, De Nicola AF, Rainbow TC, McEwen BS. Further studies of brain aldosterone binding sites employing new mineralocorticoid and glucocorticoid receptor markers in vitro. Brain Res. 1985;361:212-216.
26. Gómez-Sánchez EP, Fort CM, Gómez-Sánchez CE. Intracerebroventricular infusion of RU28318 blocks aldosterone-salt hypertension. Am J Physiol. 1990;258:E482-E484.
27. Siffert W, Dusing R. Sodium-proton exchange and primary hypertension: an update. Hypertension. 1995;26:649-655.
28. + antiporter phenotype, abundance, and phosphorylation of immortalized lymphoblasts from humans with hypertension. Hypertension. 1995;25:971-977.
29. + exchanger isoforms 1 and 3 in kidney proximal tubules of hypertensive rats. Circ Res. 1997;80:853-860.
30. + antiporter (NHE1 isoform) in cultured vascular smooth muscle from the spontaneously hypertensive rat. Kidney Int. 1995;47:78-87.
31. Kornel L. Colocalization of 11β-hydroxysteroid dehydrogenase and mineralocorticoid receptors in cultured vascular smooth muscle cells. Am J Hypertens. 1994;7:100-103.
32. Hirasawa G, Sasano H, Takahashi K, Fukushima K, Suzuki T, Hiwatashi N, Toyota T, Krozowski ZS, Nagura H. Colocalization of 11β-hydroxysteroid dehydrogenase type II and mineralocorticoid receptor in human epithelia. J Clin Endocrinol Metab. 1997;82:3859-3863.
33. Hatakeyama H, Inaba S, Miyamori I. 11β-Hydroxysteroid dehydrogenase in cultured human vascular cells: possible role in the development of hypertension. Hypertension. 1999;33:1179-1184.
34. Stewart PM, Walker BR, Holder G, O'Halloran D, Shackleton CH. 11β-Hydroxysteroid dehydrogenase activity in Cushing's syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotrophin syndrome. J Clin Endocrinol Metab. 1995;80:3617-3620.
35. Funder JW. Glucocorticoid and mineralocorticoid receptors: biology and clinical relevance. Annu Rev Med. 1997;48:231-240.
36. Vegetal E, Allan GF, Schrader WT, Tsai MJ, McDonnell DP, O'Malley BW. The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. Cell. 1992;69:703-713.
37. Meyer ME, Pornon A, Ji JW, Bocquel MT, Chambon P, Gronemeyer H. Agonistic and antagonistic activities of RU486 on the functions of the human progesterone receptor. EMBO J. 1990;9:3923-3932.
38. Li M, Wen C, Fraser T, Whitworth J. Adrenocorticotrophin-induced hypertension: effects of mineralocorticoid and glucocorticoid receptor antagonism. J Hypertens. 1999;17:419-426.
39. Morita H, Cozza EN, Zhou MY, Gómez-Sánchez EP, Romero DG, Gómez-Sánchez CE. Regulation of the 11β-hydroxysteroid dehydrogenase in the rat adrenal: decrease enzymatic activity induced by ACTH. Endocrine. 1997;7:331-335.